<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760197</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0136</org_study_id>
    <nct_id>NCT04760197</nct_id>
  </id_info>
  <brief_title>ASIA Study : French Register of Inflammatory Eye Disease</brief_title>
  <acronym>ASIA</acronym>
  <official_title>ASIA Study: French Register of Inflammatory Eye Disease Secondary to Cancer Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New anticancer therapies based on lifting the inhibition of the immunological synapse are&#xD;
      used in the therapeutic arsenal of a growing number of neoplasias (melanoma, lung cancer,&#xD;
      hepatocellular carcinoma, etc.). These &quot;immune check points&quot; inhibitors &quot;(ICPI) target&#xD;
      molecules that usually allow immunity to destroy malignant cells. At the systemic level, this&#xD;
      results in a loss of immune homeostasis and facilitation of the inflammatory response which&#xD;
      may be responsible for dysimmune manifestations distant from the neoplastic site. Thus, since&#xD;
      their introduction, ICPIs have been of interest to immunologists, rheumatologists and&#xD;
      internists who often find themselves in the first line to deal with this type of side effect&#xD;
      (immunotherapy-related adverse events, IRAEs). The frequency of these ARIs between 70% and&#xD;
      90%, depending on the immunotherapy used and the severity of these ARIIs (grade 1-2 vs. 3-5).&#xD;
      The overall increase in the number of cancers, the multiplication of available molecules and&#xD;
      the expansion of their indications should exponentially increase the number of IRAEs to be&#xD;
      supported. Little is known about the epidemiology, risk factors and efficacy of treatments.&#xD;
&#xD;
      In these IRAEs, inflammatory ophthalmological manifestations have been described with an&#xD;
      estimated prevalence of between 0.4 and 1% of the patients treated. These attacks are rare&#xD;
      and protean (uveitis, scleritis, retinitis, inflammatory orbitopathies, Vogt-Koyanagi-Harada&#xD;
      -like…) and reported most often in the form of clinical cases.&#xD;
&#xD;
      The Main objective is to describe the inflammatory ophthalmic disorders linked to anti-cancer&#xD;
      immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evolution of inflammatory ophtalmological manifestation evaluated by gradation of uveitis</measure>
    <time_frame>6 months after diagnosis</time_frame>
    <description>Persistence of disease is characterized by persistence of intraocular inflammation evaluated by gradation of Uveitis according to Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Patients Treated for Cancer by Immunotherapy</condition>
  <arm_group>
    <arm_group_label>patient under cancer immunotherapy with inflammatory ophthalmological manifestations</arm_group_label>
    <description>patient(&gt;18 years old) under cancer immunotherapy with inflammatory ophthalmological manifestations</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>patient under cancer immunotherapy with inflammatory ophthalmological manifestations</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated for cancer by immunotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt; 18&#xD;
&#xD;
          -  under cancer immunotherapy: anti-PD1 (nivolumab, pembrolizumab), anti-CTLA4&#xD;
             (ipilimumab), anti-PDL1 (atezolizumab, durvalumab, avelumab)&#xD;
&#xD;
          -  diagnosis of uveitis / inflammatory ophthalmologic disease confirmed by at least an&#xD;
             ophthalmologist&#xD;
&#xD;
          -  indicating his/her non-opposition to participating in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Chaudot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>: Hospices Civils de Lyon - Groupement Hospitalier Nord</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Chaudot, MD</last_name>
    <phone>4 26 73 26 36</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.chaudot@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvan Jamilloux, MD</last_name>
    <phone>4 26 73 26 36</phone>
    <phone_ext>+33</phone_ext>
    <email>yvan.jamilloux@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers - Service de Médecine Interne - Immunologie Clinique</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Lozach, MD</last_name>
      <phone>2 41 35 36 37</phone>
      <phone_ext>+33</phone_ext>
      <email>Pierre.LozacH@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix-Rousse - Service de médecine interne - 103 Grande Rue de la Croix-Rousse</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvan Jamilloux, MD</last_name>
      <phone>4 26 73 26 36</phone>
      <phone_ext>+33</phone_ext>
      <email>yvan.jamilloux@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune check points&quot; inhibitors</keyword>
  <keyword>cancer</keyword>
  <keyword>inflammatory ophthalmological manifestations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

